ISPOR Barcelona 2018 Schedule

 

Saturday, 10 November  •  ISPOR Pre-conference Short Courses

8:00 -12:00

Conjoint analysis - theory & methods. Hauber AB, Marshall D.

13:00 - 17:00

Collecting health-state utility estimates for economic models in clinical studies. Briggs A, Doward L, Lloyd A, Wolowacz SE.

Sunday, 11 November  •  ISPOR Pre-conference Short Courses

8:00 - 12:00

Budget impact analysis I: a 6-step approach. Brodtkorb TH, Earnshaw SR, Mullins CD.

13:00 - 17:00

Budget impact analysis II: applications & design issues. Brodtkorb TH, Brogan AJ, Earnshaw SR 

Monday, 12 November  •  ISPOR Scientific Contributions

8:45 - 13:45

Poster Session I

Patient access to new medicines; the changing landscape. (PCP10) Richardson TD, Ling C.

Regenerative medicine: a proposed classification for HEOR based on therapeutic strategy and technology type. (PCP70) Purser M, Mladsi DM.

A global review of quality of life impact of atopic dermatitis in children. (PIH54) Miles L, Purser M.

Cost per responder of secukinumab compared to other biologics in moderate-to-severe plaque psoriasis from the private payer perspective in Brazil. (PSS31) Suzuki C, Lopes N, Gilloteau I, Graham C.

Secukinumab as first biologic treatment: a cost per responder analysis compared with licensed biologics, for moderate to severe psoriasis in Argentina. (PSS33) Bianculli PM, Salibe M, Peirano I, Gilloteau I, Graham C.

Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared to ustekinumab and etanercept in Tunisia. (PSS41) Kooli A, Graham C, Scheuer N, Gilloteau I, Miles L, Sherif B, McBride D.

Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared to ustekinumab and etanercept in Morocco. (PSS42) Kooli A, Graham C, Scheuer N, Gilloteau I, Miles L, Sherif B, McBride D.

The most influential drivers of psoriasis patients’ treatment choice: a discrete choice experiment survey in the US. (PSS68) Poulos C, Feldman SR, Gilloteau I, Boeri M, Guana A, Germino B, Boehm K, Gutknecht M, Augustin M.

Identification of potential bias from data sources and study designs used to estimate platelet transfusion adverse event rates. (PSY2) Mladsi DM, Barnett CL, Kaye JA.

HTA and reimbursement considerations for rare diseases in European markets: what are the implications for manufacturers? (PSY184) Heyes A, McBride D, Pearson I, Copley-Merriman C.

15:45 - 19:15

Poster Session II

Projected burden of vaccine-preventable diseases in older adults in the United States: impact of population aging. (PIN25) Talbird SE, La EM, Carrico J, Poston S, Poirrier J, DeMartino JK, Hogea C.

The public health and economic impact of increased screening and immediate initiation of antiretroviral treatment for HIV-1 in the UK. (PIN32) Davis A, Brogan AJ, Talbird SEWild L, Flanagan D.

In small doses: missing the booster dose in a reduced pneumococcal conjugate vaccination schedule. (PIN82) Lucas A, Wilson M, Brogan AJ, Wasserman M, Jones D, Hilton B, Farkouh R.

Recent trends in meningococcal disease-related inpatient care in the United States. (PIN90).

Candrilli SD, Kurosky S.

A cost-effectiveness analysis using real-world data from the MSBase Registry: comparing natalizumab to fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in Italy. (PND55) Herring W, Gould IG, Casamassima G, Dort T, Zhang Y, Acosta C, Hyde R, Spelman T, Butzkueven H.

A cost-effectiveness analysis using real-world data from the MSBase Registry: comparing natalizumab to fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in Spain. (PND56) Herring W, Gould IG, Ruiz L, Dort T, Zhang Y, Acosta C, Hyde R, Spelman T, Butzkueven H.

Tuesday, 13 November  •  ISPOR Scientific Contributions

8:45 - 13:30

Poster Session III

Cost-effectiveness of vedolizumab versus ustekinumab in United Kingdom Crohn's disease patients who previously failed TNF inhibitor therapy. (PGI22)

Wilson M, Lucas A.

Psychometric evaluation of the diary for irritable bowel syndrome symptoms - constipation (DIBSS-C). (PGI46) Fehnel S, Ervin C, McLeod L, Carson RT, Reasner D, Hanlon J, Eremenco S, Coons SJ, PRO Consortium’s Irritable Bowel Syndrome Working Group.

European “real-world” evidence for drugs and devices: 2017 literature reviewed. (PHP255)

Mordin M, Castro C, Buck PM, Fernandez MM, Hollis KA, Ritchey ME.

Review of possible causes of variation in National Institute for Health and Care Excellence (NICE) technology appraisals. (PHP295) Ling C, Nuabor W, Lyall M, Stevenson A.

The rise of NICE advice on the use of pharmaceuticals, medical devices and digital health care in the NHS. (PHP314) Stevenson A, Ling C, Unsworth H.

NICE: a multiprogram HTA organization to suit all? (PHP324) Stevenson A, Carter K, Millar L, Ling C.

14:00 - 15:00
Workshop

Understanding and addressing potential bias in patient-reported outcomes from clinical trials. (W10) Chassany O, Knoll S, Manson S, Stull D.

15:30 - 19:00

Poster Session IV

Evaluation of data collection duration in retrospective noninterventional medical record review oncology studies conducted in the United States (US), Canada, United Kingdom (UK), Germany, France and Spain. (PRM104) Levine C, Ansquer V, Kurosky S.

Economic modelling considerations in rare diseases: a targeted review of highly specialised technology appraisals. (PRM127) Rothwell B.

An evaluation of survival curve extrapolation techniques using long-term observational cancer data. (PRM159) Vickers AD, Hawe E.

A systematic review of utility estimates in melanoma in the adjuvant setting. (PRM187) Masaquel C, Rothwell B, Bhaila R, Copley-Merriman C, Wolowacz S, Aguiar-Ibanez R, Patel N, Liu FX.

A critique of YouTube™ as a data source for the qualitative exploration of patient-reported information on acute myeloid leukemia. (PRM205) Crawford R, Bell T, Rushton R, Doward L.

Network meta-analysis in the presence of non-proportionality: a review of NICE submissions. (PRM221) Le Moine JG, Hawe E, Abeysinghe S.

The missing data problem: using propensity scores to estimate non-randomised treatment effects with missing covariate data. (PRM223) Rasouliyan L, Plana E, Martinez D, Aguado J, Ziemiecki R.

16:00 - 16:15
Podium

From drug-delivery device to disease management tool: a study of patient preferences for enhanced features in next-generation self-injection devices. (P10: MD3) Boeri M, Szegvari B, Hauber AB, Mange B, Mountian I, Schiff M, Maniadakis N.

16:15 - 16:30
Podium

Digital healthcare evaluation at NICE: an evolving process. (P10: MD4) Unsworth H, Stevenson A.

Wednesday, 14 November  •  ISPOR Scientific Contributions

8:45 - 13:15

Poster Session V

Treatments and health care utilisation (HCU) following initial platinum therapy in patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): a medical record review in Germany. (PCN257) Parikh RC, Kurosky S, Kaye JA, Levine C, Hettle R, Shire N, Sawyer W, Wang H.

Assessment of treatments and health care utilisation (HCU) in Spain following initial platinum therapy for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). (PCN264) Parikh RC, Kurosky S, Kaye JA, Levine C, Hettle R, Shire N, Sawyer W, Wang H.

Treatments and health care utilisation (HCU) in patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) following initial platinum therapy in the United Kingdom. (PCN268) Parikh R, Kurosky S, Kaye JA, Levine C, Hettle R, Shire N, Mann H, Wang H.

Time trends in frontline systemic therapy utilization for chronic lymphocytic leukemia in the United States. (PCN335) Goyal R, Nagar S, Davis KL, Kaye JA.

HR+/HER2− advanced breast cancer treatment, disease progression, and survival in Argentina, Brazil, Chile, Colombia, and Mexico. (PCN337) Levine C, Kurosky S, Kaye JA, Esterberg E, Suarez LA, Zhan L, Iyer S.

Metastatic colorectal cancer (MCRC) – literature review on quality of life instruments. (PCN390) Lebioda A, Krieger T, Kuhn A.